Search research articles
Contact Us
Filters
Showing results (201-210 of 284) with videos related to
Page
of 29
Sort By:
International Journal of Cancer
|
March 12, 2019
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3
Ryuma Tokunaga, Shu Cao, Madiha Naseem, et al.
Clinical Colorectal Cancer
|
July 10, 2023
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Beatrice Borelli, Veronica Conca, Martina Carullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2023
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taieb, et al.
British Journal of Cancer
|
June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Molecular Cancer Therapeutics
|
August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
Oncotarget
|
September 19, 2015
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Bruno Vincenzi, Chiara Cremolini, Andrea Sartore-Bianchi, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Giovanni Fucà, Francesca Corti, Margherita Ambrosini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 12, 2025
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
Arvind Dasari, Cathy Eng, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2021
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
Carlotta Antoniotti, W Michael Korn, Federica Marmorino, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 9, 2015
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
Filippo Pietrantonio, Giuseppe Aprile, Lorenza Rimassa, et al.
Page
of 29
Search research articles
Search
Showing results (201-210 of 284) with videos related to
Sort By:
Page
of 29
International Journal of Cancer
|
March 12, 2019
AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3
Ryuma Tokunaga, Shu Cao, Madiha Naseem, et al.
Clinical Colorectal Cancer
|
July 10, 2023
ShorTrip Trial: A Prospective, Multicentric Phase II Single-Arm Trial of Short-Course Radiotherapy Followed by Intensified Consolidation Chemotherapy With the Triplet FOLFOXIRI as Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer
Beatrice Borelli, Veronica Conca, Martina Carullo, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2023
Transcriptomic Signatures of MSI-High Metastatic Colorectal Cancer Predict Efficacy of Immune Checkpoint Inhibitors
Claire Gallois, Matteo Landi, Julien Taieb, et al.
British Journal of Cancer
|
June 6, 2022
Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter?
Roberto Moretto, Andrew Elliott, Daniele Rossini, et al.
Molecular Cancer Therapeutics
|
August 5, 2020
Prognostic and Predictive Biomarkers in Patients with Metastatic Colorectal Cancer Receiving Regorafenib
Yingmiao Liu, Jing Lyu, Kirsten Bell Burdett, et al.
Oncotarget
|
September 19, 2015
Prognostic significance of K-Ras mutation rate in metastatic colorectal cancer patients
Bruno Vincenzi, Chiara Cremolini, Andrea Sartore-Bianchi, et al.
Journal for Immunotherapy of Cancer
|
April 14, 2021
Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors
Giovanni Fucà, Francesca Corti, Margherita Ambrosini, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 12, 2025
Fruquintinib in less pretreated patients: Multivariate profile-matching analysis of FRESCO-2 to FRESCO
Arvind Dasari, Cathy Eng, Sara Lonardi, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 8, 2021
Tumour mutational burden, microsatellite instability, and actionable alterations in metastatic colorectal cancer: Next-generation sequencing results of TRIBE2 study
Carlotta Antoniotti, W Michael Korn, Federica Marmorino, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
September 9, 2015
A new nomogram for estimating survival in patients with brain metastases secondary to colorectal cancer
Filippo Pietrantonio, Giuseppe Aprile, Lorenza Rimassa, et al.
Page
of 29